Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Sell
50
MDT Quote, Financials, Valuation and Earnings
Last price:
$88.64
Seasonality move
:
4.65%
Day range:
$88.21 - $89.59
52-week range:
$75.96 - $96.25
Dividend yield:
3.16%
P/E ratio:
26.90x
P/S ratio:
3.46x
P/B ratio:
2.30x
Volume:
6.9M
Avg. volume:
8M
1-year change:
1.69%
Market cap:
$113.5B
Revenue:
$32.4B
EPS (TTM):
$3.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$8.3B | $1.36 | 2.61% | 221.83% | $97.05 |
|
ABT
Abbott Laboratories
|
$10.4B | $1.07 | 4.17% | 52.09% | $136.68 |
|
BSX
Boston Scientific
|
$4.6B | $0.67 | 18.57% | 103.68% | $115.53 |
|
PODD
Insulet
|
$543.5M | $0.78 | 23.07% | 6.17% | $314.06 |
|
SYK
Stryker
|
$5.7B | $2.73 | 8.36% | 33.41% | $423.76 |
|
TMDX
TransMedics Group
|
$123.4M | $0.24 | 27.41% | -31.06% | $102.86 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$88.49 | $97.05 | $113.5B | 26.90x | $0.70 | 3.16% | 3.46x |
|
ABT
Abbott Laboratories
|
$131.69 | $136.68 | $228.4B | 17.21x | $0.59 | 1.7% | 5.49x |
|
BSX
Boston Scientific
|
$101.24 | $115.53 | $149.4B | 80.99x | $0.00 | 0% | 8.98x |
|
PODD
Insulet
|
$263.18 | $314.06 | $18.5B | 45.45x | $0.00 | 0% | 9.39x |
|
SYK
Stryker
|
$373.30 | $423.76 | $142.4B | 48.11x | $0.84 | 0.88% | 6.37x |
|
TMDX
TransMedics Group
|
$68.27 | $102.86 | $2.3B | 67.59x | $0.00 | 0% | 5.45x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MDT
Medtronic PLC
|
34.97% | 0.718 | 22.74% | 1.19x |
|
ABT
Abbott Laboratories
|
22.86% | 0.777 | 7.72% | 1.23x |
|
BSX
Boston Scientific
|
32.79% | 0.797 | 8.05% | 0.46x |
|
PODD
Insulet
|
53.47% | 1.438 | 7.6% | 2.50x |
|
SYK
Stryker
|
39.72% | 1.207 | 10.13% | 1.11x |
|
TMDX
TransMedics Group
|
69.02% | 2.597 | 24.3% | 7.25x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MDT
Medtronic PLC
|
$5.5B | $1.7B | 5.58% | 8.56% | 20.73% | $2.1B |
|
ABT
Abbott Laboratories
|
$6B | $1.9B | 24.06% | 32.63% | 19.74% | $2.1B |
|
BSX
Boston Scientific
|
$3.1B | $790M | 5.97% | 8.96% | 14.58% | $1.2B |
|
PODD
Insulet
|
$430.9M | $109.3M | 17.64% | 43.11% | 20.08% | $91.7M |
|
SYK
Stryker
|
$4.2B | $1.6B | 9.04% | 15.22% | 24.21% | $1.7B |
|
TMDX
TransMedics Group
|
$72M | $8.6M | 5.12% | 19.17% | 8.68% | $6.1M |
Medtronic PLC vs. Competitors
-
Which has Higher Returns MDT or ABT?
Abbott Laboratories has a net margin of 15.61% compared to Medtronic PLC's net margin of 84.1%. Medtronic PLC's return on equity of 8.56% beat Abbott Laboratories's return on equity of 32.63%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B ABTAbbott Laboratories54.97% $5.27 $62B -
What do Analysts Say About MDT or ABT?
Medtronic PLC has a consensus price target of $97.05, signalling upside risk potential of 9.68%. On the other hand Abbott Laboratories has an analysts' consensus of $136.68 which suggests that it could grow by 3.79%. Given that Medtronic PLC has higher upside potential than Abbott Laboratories, analysts believe Medtronic PLC is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC11 14 1 ABTAbbott Laboratories13 7 0 -
Is MDT or ABT More Risky?
Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.803, suggesting its less volatile than the S&P 500 by 19.666%.
-
Which is a Better Dividend Stock MDT or ABT?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.16%. Abbott Laboratories offers a yield of 1.7% to investors and pays a quarterly dividend of $0.59 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Abbott Laboratories pays out 28.62% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or ABT?
Medtronic PLC quarterly revenues are $8.3B, which are smaller than Abbott Laboratories quarterly revenues of $11B. Medtronic PLC's net income of $1.3B is lower than Abbott Laboratories's net income of $9.2B. Notably, Medtronic PLC's price-to-earnings ratio is 26.90x while Abbott Laboratories's PE ratio is 17.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.46x versus 5.49x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.46x 26.90x $8.3B $1.3B ABTAbbott Laboratories5.49x 17.21x $11B $9.2B
-
Which has Higher Returns MDT or BSX?
Boston Scientific has a net margin of 15.61% compared to Medtronic PLC's net margin of 12.41%. Medtronic PLC's return on equity of 8.56% beat Boston Scientific's return on equity of 8.96%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B BSXBoston Scientific67.86% $0.38 $32.6B -
What do Analysts Say About MDT or BSX?
Medtronic PLC has a consensus price target of $97.05, signalling upside risk potential of 9.68%. On the other hand Boston Scientific has an analysts' consensus of $115.53 which suggests that it could grow by 14.11%. Given that Boston Scientific has higher upside potential than Medtronic PLC, analysts believe Boston Scientific is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC11 14 1 BSXBoston Scientific23 4 0 -
Is MDT or BSX More Risky?
Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.
-
Which is a Better Dividend Stock MDT or BSX?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.16%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or BSX?
Medtronic PLC quarterly revenues are $8.3B, which are larger than Boston Scientific quarterly revenues of $4.6B. Medtronic PLC's net income of $1.3B is higher than Boston Scientific's net income of $566M. Notably, Medtronic PLC's price-to-earnings ratio is 26.90x while Boston Scientific's PE ratio is 80.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.46x versus 8.98x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.46x 26.90x $8.3B $1.3B BSXBoston Scientific8.98x 80.99x $4.6B $566M
-
Which has Higher Returns MDT or PODD?
Insulet has a net margin of 15.61% compared to Medtronic PLC's net margin of 16.85%. Medtronic PLC's return on equity of 8.56% beat Insulet's return on equity of 43.11%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B PODDInsulet72.12% $1.39 $2.6B -
What do Analysts Say About MDT or PODD?
Medtronic PLC has a consensus price target of $97.05, signalling upside risk potential of 9.68%. On the other hand Insulet has an analysts' consensus of $314.06 which suggests that it could grow by 19.33%. Given that Insulet has higher upside potential than Medtronic PLC, analysts believe Insulet is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC11 14 1 PODDInsulet14 4 0 -
Is MDT or PODD More Risky?
Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.
-
Which is a Better Dividend Stock MDT or PODD?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.16%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or PODD?
Medtronic PLC quarterly revenues are $8.3B, which are larger than Insulet quarterly revenues of $597.5M. Medtronic PLC's net income of $1.3B is higher than Insulet's net income of $100.7M. Notably, Medtronic PLC's price-to-earnings ratio is 26.90x while Insulet's PE ratio is 45.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.46x versus 9.39x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.46x 26.90x $8.3B $1.3B PODDInsulet9.39x 45.45x $597.5M $100.7M
-
Which has Higher Returns MDT or SYK?
Stryker has a net margin of 15.61% compared to Medtronic PLC's net margin of 8.48%. Medtronic PLC's return on equity of 8.56% beat Stryker's return on equity of 15.22%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B SYKStryker64.85% $1.41 $34.2B -
What do Analysts Say About MDT or SYK?
Medtronic PLC has a consensus price target of $97.05, signalling upside risk potential of 9.68%. On the other hand Stryker has an analysts' consensus of $423.76 which suggests that it could grow by 13.52%. Given that Stryker has higher upside potential than Medtronic PLC, analysts believe Stryker is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC11 14 1 SYKStryker13 9 0 -
Is MDT or SYK More Risky?
Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.
-
Which is a Better Dividend Stock MDT or SYK?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.16%. Stryker offers a yield of 0.88% to investors and pays a quarterly dividend of $0.84 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or SYK?
Medtronic PLC quarterly revenues are $8.3B, which are larger than Stryker quarterly revenues of $6.4B. Medtronic PLC's net income of $1.3B is higher than Stryker's net income of $546M. Notably, Medtronic PLC's price-to-earnings ratio is 26.90x while Stryker's PE ratio is 48.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.46x versus 6.37x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.46x 26.90x $8.3B $1.3B SYKStryker6.37x 48.11x $6.4B $546M
-
Which has Higher Returns MDT or TMDX?
TransMedics Group has a net margin of 15.61% compared to Medtronic PLC's net margin of 5.64%. Medtronic PLC's return on equity of 8.56% beat TransMedics Group's return on equity of 19.17%.
Company Gross Margin Earnings Per Share Invested Capital MDTMedtronic PLC66.49% $1.01 $76.2B TMDXTransMedics Group59.21% $0.19 $737.9M -
What do Analysts Say About MDT or TMDX?
Medtronic PLC has a consensus price target of $97.05, signalling upside risk potential of 9.68%. On the other hand TransMedics Group has an analysts' consensus of $102.86 which suggests that it could grow by 50.66%. Given that TransMedics Group has higher upside potential than Medtronic PLC, analysts believe TransMedics Group is more attractive than Medtronic PLC.
Company Buy Ratings Hold Ratings Sell Ratings MDTMedtronic PLC11 14 1 TMDXTransMedics Group5 3 0 -
Is MDT or TMDX More Risky?
Medtronic PLC has a beta of 0.794, which suggesting that the stock is 20.554% less volatile than S&P 500. In comparison TransMedics Group has a beta of 2.138, suggesting its more volatile than the S&P 500 by 113.849%.
-
Which is a Better Dividend Stock MDT or TMDX?
Medtronic PLC has a quarterly dividend of $0.70 per share corresponding to a yield of 3.16%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Medtronic PLC pays 99.73% of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios MDT or TMDX?
Medtronic PLC quarterly revenues are $8.3B, which are larger than TransMedics Group quarterly revenues of $121.6M. Medtronic PLC's net income of $1.3B is higher than TransMedics Group's net income of $6.9M. Notably, Medtronic PLC's price-to-earnings ratio is 26.90x while TransMedics Group's PE ratio is 67.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Medtronic PLC is 3.46x versus 5.45x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDTMedtronic PLC3.46x 26.90x $8.3B $1.3B TMDXTransMedics Group5.45x 67.59x $121.6M $6.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 4.45% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.59% over the past day.
